Type A monoamine oxidase regulates life and death of neurons in neurodegeneration and neuroprotection

International Review of Neurobiology

Volumn 100, Issue , 2011, Pages 85-106

  Naoi, Makoto ^a   Maruyama, Wakako ^b   Inaba Hasegawa, Keiko ^a   Akao, Yukihiro ^c  

^a GIFU INTERNATIONAL INSTITUTE OF BIOTECHNOLOGY   (Japan)

^b NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^c GIFU UNIVERSITY   (Japan)

Author keywords

Apoptosis; Bcl 2; MAO inhibitors; Mitochondria; Neurodegeneration; Neuroprotection; Neurotrophic factors; Type A and B monoamine oxidase

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; BEFLOXATONE; CASPASE 2; CASPASE 9; CERAMIDE; CLORGYLINE; CYTOCHROME C; DEHYDROPIRLINDOLE; ETOPOSIDE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HARMINE; LADOSTIGIL; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; MITOGEN ACTIVATED PROTEIN KINASE P38; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; N PROPARGYLAMINE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; NEUROTROPHIC FACTOR; NEUROTROPHIN 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PIRLINDOLE; PROTEIN BCL 2; PROTEIN BCL XL; RASAGILINE; SELEGILINE; UNCLASSIFIED DRUG; VOLTAGE DEPENDENT ANION CHANNEL;

ALZHEIMER DISEASE; APOPTOSIS; BINDING SITE; BOOK; CELL DEATH; DEPRESSION; DNA POLYMORPHISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; FRONTOTEMPORAL DEMENTIA; HUMAN; INTRON; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 80053539494     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-386467-3.00005-4     Document Type: Chapter

References (130)

1. Akao Y., Maruyama W., Shimizu S., Yi H., Shamoto-Nagai M., Youdim M.B., Tsujimoto Y., Naoi M. Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J. Neurochem. 2002, 82:913-923.
2. Akao Y., Maruyama W., Yi H., Shamoto-Nagai M., Youdim M.B., Naoi M. An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline) enhances expression of antiapoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci. Lett. 2002, 326:105-108.
3. Almeida R.D., Manadas B.J., Melo C.V., et al. Neuroprotection by BDNF against glutamate-induced apoptotic cell death is mediated by ERK and PI3-kinase pathways. Cell Death Differ. 2005, 12:1329-1343.
4. Andoh T., Chock P.B., Murphy D.L., Chiueh C.C. Role of the redox protein thioredoxin in cytoprotective mechanism evoked by (-)-deprenyl. Mol. Pharmacol. 2005, 68:1408-1414.
5. Balu D.T., Hoshaw B.A., Malberg J.E., Rosenzweig-Lipson S., Schechter L.E., Lucki I. Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments. Brain Res. 2008, 1211:37-43.
6. Bar-Am O., Yogev-Talach M., Amit T., Sagi Y., Youdim M.B.H. Regulation of protein kinase C by the anti-parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo. J. Neurochem. 2004, 89:1119-1125.
7. Bar-Am O., Weinreb O., Amit T., Youdim M.B. Regulation of Bcl-2 protein family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J. 2005, 19:1899-1901.
8. Biagini G., Frasoldati A., Fuxe K., Agnati L.F. The concept of astrocyte-kinetic drug in the treatment of neurodegenerative diseases: evidence for L-Deprenyl-induced activation of reactive astrocytes. Neurochem. Int. 1994, 25:17-22.
9. Bialecka M., Klodowska-Duda G., Honczarenko K., Gawrońska-Szklarz B., Opala G., Safranow K., Droździk M. Polymorphisms of catechol-O-methyltransferase (COMT), monoamine oxidase B (MAOB), N-acetyltransferase 2 (NAT2) and cytochrome P450 2D6 (CYP2D6) gene in patients with early onset of Parkinson's disease. Parkinsonism Relat. Disord. 2007, 13:224-229.
10. Bianchi P., Kunduzova O., Masini E., et al. Oxidative stress by monoamine oxidase mediates receptor-independent cardiomyocyte apoptosis by serotonin and postischemic myocardial injury. Circulation 2005, 112:3297-3305.
11. Binda C., Hubalek F., Li M., Herzig Y., Sterling J., Edmondson D.E., Mattevi A. Crystal structures of monoamine oxidase B in complex with four inhibitors of N-propargylaminoindan class. J. Med. Chem. 2004, 47:1767-1774.
12. Birkmayer W., Riederer P., Ambrozi L., Youdim M.B.H. Implication of combined treatment with 'Madopar' and L-deprenyl in Parkinson's disease. Lancet 1977, I:439-443.
13. Biswas S.C., Greene L.A. Nerve growth factor (NGF) down-regulates the Bcl-2 homology 3 (BH3) domain-only protein Bim and suppresses its proapoptotic activity by phosphorylation. J. Biol. Chem. 2002, 277:40511-49516.
14. Biswas G., Anandatheetthavarada H.K., Zaidi M., Avadhani N.G. Mitochondria to nucleus stress signaling: a distinctive mechanism of NFκB/Rel activation through calcineurin-mediated inactivation of IκBβ. J. Cell Biol. 2003, 161:507-519.
15. Blandini F., Cosentino M., Mangiagalli A., et al. Modification of apoptosis-related protein levels in lymphocytes of patients with Parkinson's disease. The effect of dopaminergic treatment. J. Neural Transm. 2004, 111:1017-1030.
16. Boland A., Gerardy J., Mossay D., Delapierrre D., Seutin V. Pirlindole and dehydropirlindole protect rat cultured neuronal cells against oxidative stress-induced cell death through a mechanism unrelated to MAO-A inhibition. Br. J. Pharmacol. 2002, 135:713-720.
17. Bortolato M., Chen K., Shih J.C. Monoamine oxidase inactivation: from pathophysiology to therapeutics. Adv. Drug Deliv. Rev. 2008, 60:1527-1533.
18. 2 -site ligands BU224 and 2-BFI inhibit MAO-A and MAO-B activities, hydrogen peroxide production, and lipolysis in rodent and human adipocytes. Eur. J. Pharmacol. 2006, 552:20-30.
19. Brabeck C., Pfeiffer R., Leake A., Beneke S., Meyer R., Bürkle A. L-Selegiline potentiates the cellular poly(ADP-ribosyl)lation response to ionizing radiation. J. Pharmacol. Exp. Ther. 2003, 306:973-979.
20. Chen K., Ou X.-M., Chen G., Choi S.H., Chih J.C. R1, a novel repressor of the human monoamine oxidase A. J. Biol. Chem. 2005, 280:11552-11559.
21. Chen K., Cases O., Rebrin I., Wu, Gallaher T.K., Seif I., Shih J.C. Forebrain-specific expression of monoamine oxidase A reduces neurotransmitter levels, restores the brain structure, and rescues aggressive behavior in monoamine oxidase A-deficient mice. J. Biol. Chem. 2007, 282:115-123.
22. Cheng A., Scott A.L., Ladenheim B., et al. Monoamine oxidases regulate telencephalic neural progenitors in late embryonic and early postnatal development. J. Neurosci. 2010, 30:10752-10762.
23. Chiou S.H., Ku H.H., Tsai T.H., Lin H.L., Chen L.H., Chien C.S., Ho L.L.-T., Lee C.H., Chang Y.L. Moclobemide upregulated Bcl-2 expression and induce neural stem cell differentiation into serotoninergic neurons via extracellular-regulated kinase pathway. Br. J. Pharmacol. 2006, 148:587-598.
24. Cohen G., Farooqui P., Kesler N. Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow. Proc. Natl. Acad. Sci. USA 1997, 94:4890-4894.
25. Cohen I.L., Liu X., Schutz C., White B.N., Jenkins E.C., Brown W.T., Holden J.J.A. Association of autism severity with a monoamine oxidase A functional polymorphism. Clin. Genet. 2003, 64:190-197.
26. Costantini J., Rees H.D., Weintraub S.T., et al. Oxidation of a critical thiol residue of the adenine nucleotide translocator enforces Bcl-2-independent permeability transition pore opening and apoptosis. Oncogene 2000, 19:307-314.
27. Dagda R.K., Zhu J., Chu C.T. Mitochondrial kinases in Parkinson's disease: converging insights from neurotoxin and genetic models. Mitochondrion 2009, 9:289-298.
28. De Girolamo L.A., Hargreaves A.J., Billett E.E. Protection from MPTP-induced neurotoxicity in differentiating mouse N2a neuroblastoma cells. J. Neurochem. 2001, 76:650-660.
29. De Zutter G.S., Davis R.J. Pro-apoptotic gene expression mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Proc. Natl. Acad. Sci. USA 2001, 98:6169-6173.
30. Domschke K., Hohoff C., Mortensen L.S., Roehrs T., Deckert J., Arolt V., Baune B.C. Monoamine oxidase A variant influences antidepressant treatment response in female patients with Major Depression. Progr. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:224-228.
31. Ekblom J., Zhu Q.-S., Chen K., Shih J.C. Monoamine oxidase gene transcription in human cell lines: treatment with psychoactive drugs and ethanol. J. Neural Transm. 1996, 103:681-692.
32. Eslamboli A., Georgievska B., Ridley R.M., et al. Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. J. Neurosci. 2005, 25:769-777.
33. Esmaeli F., Tiraihi T., Movahedin M., Mowla S.J. Selegiline induces neuronal phenotype and neurotrophins expression in embryonic stem cells. Rejuvenation Res. 2006, 9:475-484.
34. Feher A., Juhasz A., Rimanoczy A., Kalman J., Janka Z. Association between BDNF Val66Met polymorphism and Alzheimer disease, dementia with Lewy bodies, and Pick disease. Alzheimer Dis. Assoc. Disord. 2009, 23:224-228.
35. Finberg J.P.M., Takeshima T., Johnston J.M., Commissiong J.W. Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. Neuroreport 1998, 9:703-707.
36. Finnegan K.T., Skratt J.J., Irwin I., DeLanney L.E., Langston J.W. Protection against DSP-4-induced neurotoxicity by deprenyl is not relayed to its inhibition of MAO B. Eur. J. Pharmacol. 1990, 184:119-126.
37. Fitzgerald J.C., Ufer C., De Girolamo L.A., Kuhn H., Billet E.E. Monoamine oxidase-A modulates apoptotic cell death induced by staurosporine in human neuroblastoma cells. J. Neurochem. 2007, 103:2189-2199.
38. Fortunato J.J., Reus G.Z., Kirsch T.R., et al. Chronic administration of harmine elicits antidepressant-like effects and increases BDNF levels in rat hippocampus. J. Neural Transm. 2010, 117:1131-1137.
39. Fowler J.S., Volkow N.D., Wang G.J., Logan J., Pappas N., Shea C., MacGregor R. Age-related increases in brain monoamine oxidase B in living healthy human subjects. Neurobiol. Aging 1997, 198:431-435.
40. Gal S., Zheng H., Fridkin M., Youdim M.B.H. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J. Neurochem. 2005, 95:79-88.
41. Gao X., Scott W.K., Wang G., Mayhew G., Li Y.J., Vance J.M., Martin E.R. Gene-gene interaction between FGF20 and MAOB in Parkinson disease. Ann. Hum. Genet. 2008, 72(Pt 2):157-162.
42. Gelowitz D.L., Paterson I.A. Neuronal sparing and behavioral effects of the antiapoptotic dug, (-)deprenyl, following kainic acid administration. Pharmacol. Biochem. Behav. 1999, 62:255-262.
43. Grimsby J., Toth M., Chen K., et al. Increased stress response and β-phenylethylamine in MAOB-deficient mice. Nat. Genet. 1997, 17:206-210.
44. Gyarfas T., Knuuttila J., Lindholm P., Rantamaki T., Castren E. Regulation of brain-derived neurotrophic factors (BDNF) and cerebral dopamine neurotrophic factor (CDNF) by anti-parkinsonian drug therapy in vivo. Cell. Mol. Neurobiol. 2010, 30:361-368.
45. Heikkila R.E., Manzino L., Cabbat F.S., Duvoisin R.N. Protection against dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 1984, 311:467-469.
46. Heikkila R.E., Kindt M.V., Sonsalla P.K., Giovanni A., Youngster S.K., McKeown K.A., Singer T.P. Importance of monoamine oxidase A in the bioactivation of neurotoxic analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydroptridine. Proc. Natl. Acad. Sci. USA 1988, 85:6172-6176.
47. Henkel A.W., Sperling W., Rotter A., et al. Antidepressant drugs modulates growth factors in cultured cells. BMC Pharmacol. 2008, 8:6.
48. Holt A., Wieland B., Boulton A.A. On the binding site of monoamine oxidase inhibitors to some sites distinct from the MAO active site, and effects thereby elicited. Neurotoxicology 2004, 25:251-266.
49. Hong M., Mukhida K., Mendez I. GDNF therapy for Parkinson's disease. Expert Rev. Neurother. 2008, 8:11125-11139.
50. Horbinski C., Chu C.T. Kinase signaling cascades in the mitochondria: a matter of life or death. Free Radic. Biol. Med. 2005, 38:2-11.
51. Huang W., Chen Y., Shohami E., Weinstock M. Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur. J. Pharmacol. 1999, 366:127-135.
52. Inaba-Hasegawa, K., Akao, Y., Maruyama, W., and Naoi, M. Type A monoamine oxidase is associated with the induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase. (in preparation).
53. Jang J.-H., Surh Y.-J. Bcl-2 attenuation of oxidative cell death is associated with up-regulation of γ-glutamyl cysteine ligase via constitutive NF-κB activation. J. Biol. Chem. 2004, 279:38779-38786.
54. Jellinger K.A. Cell death mechanisms in neurodegeneration. J. Cell. Mol. Med. 2001, 5:1-17.
55. Kennedy B.P., Ziegler M.G., Alford M., Hansen L.A., Thal L.J., Masliah E. Early and persistent alterations in frontal cortex MAO A and B in Alzheimer's disease. J. Neural Transm. 2003, 110:789-801.
56. Kitamura Y., Shimohama S., Kamoshima W., et al. Alteration of proteins regulating apoptosis, Bcl-2, Bcl-x, Bax, Bak, Bad, ICH-1 and CPP32 in Alzheimer's disease. Brain Res. 1998, 780:260-269.
57. Knoll J., Yoneda F., Knoll B., Ohde H., Miklya I. (-)1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. Br. J. Pharmacol. 1999, 128:1723-1732.
58. Kroemer G., Galluzzi L., Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 2007, 87:99-163.
59. Kumar M.J., Nicholls D.G., Andersen J.A. Oxidative α-ketoglutarate dehydrogenase inhibition via subtle elevation in monoamine oxidase B levels results in loss of spare respiratory capacity. J. Biol. Chem. 2003, 278:46432-46439.
60. Kunduzova O.R., Bianchi P., Pizzinat N., Escourrou G., Seguelas M.-H., Parini A., Cambon G. Regulation of JNK/ERK activation, cell apoptosis, and tissue regeneration by monoamine oxidases after renal ischemia-reperfusion. FASEB J. 2002, 16:1129-1131.
61. Lang A.E., Gill S., Patel N.K., et al. Randomized controlled trial of intraputmental glial cell line-derived neurotrophic factor infusion in Parkinson's disease. Ann. Neurol. 2006, 59:459-466.
62. Lee J.G., Cho H.Y., Park S.W., Seo M.K., Kim Y.H. Effects of olanzapine on brain-derived neurotrophic factor gene promotor activity in SH-SY5Y neuroblastoma cells. Prog. Neuropsychopharm. Biol. Psychiatry 2010, 34:1001-1006.
63. 3 H]quinpirole binding by monoamine oxidase inhibitors. Life Sci. 2002, 71:2691-2700.
64. Lin C.-F., Chen C.-L., Chang W.-T., et al. Bcl-2 rescues ceramide- and etoposide-induced mitochondrial apoptosis through blockage of caspase-2 activation. J. Biol. Chem. 2005, 280:23758-23765.
65. Lindholm P., Voutilainen M.H., Lauren J., et al. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature 2007, 448:73-77.
66. Maher P., Davis J.B. The role of monoamine metabolism in oxidative glutamate toxicity. J. Neurosci. 1996, 16:6394-6401.
67. Maragos W.F., Young K.L., Altman C.S., et al. Striatal damage and oxidative stress induced by the mitochondrial toxin malonate are reduced in clorgyline and MAO-A deficient mice. Neurochem. Res. 2004, 29:741-746.
68. Maruyama W., Naoi M., Kasamatsu T., Hashizume Y., Takahashi T., Kohda K., Dostert P. An endogenous dopaminergic neurotoxin, N-methyl-(R)-salsolinol, induces DNA damage in human dopaminergic neuroblastoma SH-SY5Y cells. J. Neurochem. 1997, 69:322-329.
69. Maruyama W., Akao Y., Youdim B.B.H., Davis B.A., Naoi M. Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. J. Neurochem. 2001, 68:727-735.
70. Maruyama W., Takahashi T., Youdim M., Naoi M. The anti-parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J. Neural Transm. 2002, 109:467-481.
71. Maruyama W., Weinstock M., Youdim M.B.H., Nagai M., Naoi M. Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-amnoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor. Neurosci. Lett. 2003, 341:233-236.
72. Maruyama W., Nitta A., Shamoto-Nagai M., Hirata Y., Akao Y., Youdim M., Furukawa S., Nabeshima T., Naoi M. N-Propargyl-1-(R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-κB transcription factor. Neurochem. Int. 2004, 44:293-400.
73. Maruyama W., Yi H., Takahashi T., Shimazu S., Ohde H., Yoneda F., Iwasa K., Naoi M. Neuroprotective function of R-(-)1-(benzofuran-2-yl)-2-propyl-aminopentane, [R-(-)-BPAP], against apoptosis induced by N-methyl(R)salsolinol, an endogenous dopaminergic neurotoxin, in human dopaminergic neuroblastoma SH-SY5Y cells. Life Sci. 2004, 75:107-117.
74. Maruyama, W., Nitta, A., Suzuki, J., and Naoi, M. Induction of glial cell line-derived neurotrophic factor and neurotrophin in non-human primate by rasagiline and selegiline. (in preparation).
75. Mattson M.P., Gleichmann M., Cheng A. Mitochondria in neuroplasticity and neurological disorders. Neuron 2008, 60:748-766.
76. + ) binds with high affinity to a β-carboline binding site localized on monoamine oxidase type A in rat brain. Neurosci. Lett. 1993, 162:55-58.
77. Mele T., Carman-Krzan M., Juric D.M. Regulatory role of monoamine neurotransmitters in astrocytic NT-3 synthesis. Int. J. Dev. Neurosci. 2010, 28:13-19.
78. Mizuta I., Ohta M., Ohta K., Nishimura M., Mizuta E., Hayashi K., Kuno S. Selegiline and desmethylselegiline stimulate NGF, BDNF, and GDNF synthesis in cultured mouse astrocytes. Biochem. Biophys. Res. Commun. 2000, 279:751-755.
79. Morgan M.J., Liu Z.-G. Crosstalk of reactive oxygen species and NF-κB signaling. Cell Res. 2010, 21:103-115.
80. Nakaso K., Nakamura C., Sato H., Imamura K., Takesima T., Nakashima K. Novel cytoprotective mechanism of anti-parkinsonian drug deprenyl: PI3K and Nrf2-derived induction of antioxidative proteins. Biochem. Biophys. Res. Commun. 2006, 339:915-922.
81. Naoi M., Maruyama W. Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease. Expert Rev. Neurother. 2009, 9:1233-1250.
82. Naoi M., Maruyama W. Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders. Curr. Pharmaceut. Design 2010, 16:2799-2817.
83. Naoi M., Maruyama W., Nagy G.M. Dopamine-derived salsolinol derivatives as endogenous monoamine oxidase inhibitors: occurrence, metabolism and function in human brain. Neurotoxicology 2004, 25:193-204.
84. Naoi M., Maruyama W., Akao Y., Yi H., Yamaoka T. Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading cell death or neuroprotection. J. Neural Transm. Suppl. 2006, 71:67-77.
85. Naoi M., Maruyama W., Yi H., Akao Y., Yamaoka Y., Shamoto-Nagai M. Neuroprotection by propargylamines in Parkinson's disease: intracellular mechanism underlying the anti-apoptotic function and search for clinical markers. J. Neural Transm. Suppl. 2007, 72:121-131.
86. Naoi M., Maruyama W., Yi H., et al. Neuromelanin selectively induces apoptosis in dopaminergic SH-SY5Y cells by deglutathionylation in mitochondria: involvement of the protein and melanin component. J. Neurochem. 2008, 105:2489-2500.
87. Naoi, M., Maruyama, W., and Yi, H. Role of monoamine oxidase in apoptosis induced by imidazolines and ligands for 18-kDA-translocator protein. (in preparation).
88. Ohta M., Mizuta I., Ohta K., Nishimura M., Mizuta E., Hayashi K., Kuno S. Apomorphine up-regulates NGF and GDNF synthesis in cultured mouse astrocytes. Biochem. Biophys. Res. Commun. 2000, 272:18-22.
89. Ohta K., Fujinami A., Kuo S., Sakakimoto A., Matsui H., Kawahara Y., Ohta M. Cabergoline stimulates synthesis and secretion of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor by mouse astrocytes in primary culture. Pharmacology 2004, 71:162-168.
90. Ou X.-M., Chen K., Shih J.C. Monoamine oxidase A and repressor R1 are involved in apoptotic signaling pathway. Proc. Natl. Acad. Sci. USA 2006, 103:10923-10928.
91. Ou X.-M., Johnson C., Chen K., Youdim M.B., Rajkowska G., Shih J.C. Glyceraldehyde-3-phosphare dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox. Res. 2009, 16:148-159.
92. 2 -imidazoline receptors in rat liver. Br. J. Pharmacol. 1997, 121:901-912.
93. Effects of tocopherol and deprenyl on progression of disability in early Parkinson's disease. N. Engl. J. Med. 1993, 328:176-183. Parkinson Study Group.
94. Parsian A., Racette B., Zhang Z.H., Rundle M., Perlmutter J.S. Association of variations in monoamine oxidases A and B with Parkinson's disease subgroups. Genomics 2004, 83:454-460.
95. Pascual A., Hidalgo-Figuerosa M., Piruat J., Pintado C.O., Gomez-Diaz R., Lopez-Barneo J. Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat. Neurosci. 2008, 11:755-761.
96. Petrova P., Raibekas A., Pevsner J., et al. MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons. J. Mol. Neurosci. 2003, 20:173-188.
97. Qiu W.-W., Zheng R.-Y. Neuroprotective effects of receptor imidazoline 2 and its endogenous ligand agmatine. Neurosci. Bull. 2006, 22:187-191.
98. Raddatz R., Parini A., Lanier S.M. Localization of the imidazoline binding domain on monoamine oxidase B. Mol. Pharmacol. 1997, 52:549-553.
99. Reif A., Scapini E., Venturelli E., Töpner T., Fenoglio C., Lesch K.P., Galimberti D. The functional MAOA-uVNTR promoter polymorphism in patients with frontotemporal dementia. Eur. J. Neurol. 2008, 15:637-639.
100. Ricci A., Mancini M., Strocchi P., Bongrani S., Bronzetti E. Deficits in cholinergic neurotransmission markers induced by ethylcholine mustard aziridinium (AF64A) in the rat hippocampus: sensitivity to treatment with the monoamine oxidase-B inhibitor L-deprenyl. Drugs Exp. Clin. Res. 1992, 18:163-171.
101. Riederer P., Lachenmayer L., Laux G. Clinical applications of MAO-inhibitors. Curr. Med. Chem. 2004, 11:2033-2043.
102. Roohi J., DeVincent C.J., Hatchwell E., Gadow K.D. Association of a monoamine oxidase-a promoter polymorphism with ADHD and anxiety in boys with autism spectrum disorder. J. Autism Dev. Disord. 2009, 39:67-74.
103. Sagi Y., Mandel S., Amit T., Youdim M.B. Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol. Dis. 2003, 25:35-44.
104. + -treated SH-SY5Y human dopaminergic cells. J. Neurochem. 2008, 105:2404-2417.
105. Sariola H., Saarma M. Novel functions and signaling pathways for GDNF. J. Cell Sci. 2003, 116:3853-3862.
106. Semkova I., Wolz P., Schilling M., Krieglstein J. Selegiline enhances NGF synthesis and protects central nervous system neurons from excitotoxic and ischemic damage. Eur. J. Pharmacol. 1996, 315:19-30.
107. Seniuk N.A., Henderson J.T., Tatton W.G., Roder J.C. Increased CNTF gene expression in process-bearing astrocytes following injury is augmented by R(-)-deprenyl. J. Neurosci. Res. 1994, 37:278-286.
108. Shachar D.B., Kahana N., Kampel V., Warshawsky A., Youdim M.B. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroy dopamine lesion in rats. Neurophamacology 2004, 46:254-263.
109. Shacka J.J., Roth K.A. Regulation of neuronal cell death and neurodegeneration by members of the Bcl-2 family: therapeutic implications. Curr. Drug Targets-CNS Neurol. Dis. 2005, 4:25-39.
110. Shih J.C., Thompson R.F. Monoamine oxidase in neuropsychiatry and behavior. Am. J. Hum. Genet. 1999, 65:593-598.
111. Shih J.C., Chen K., Ridd M.J. Monoamine oxidase: from genes to behavior. Annu. Rev. Neurosci. 1999, 22:197-217.
112. Shimazu S., Tanigawa A., Sato N., Yoneda F., Hayashi K., Knoll J. Enhancer substrates: selegiline and R-(-)-1-(benzofuran-2-yl9-2-propylaminopentane [(-)-BPAP] enhances the neurotrophic factor synthesis on cultured mouse astrocytes. Life Sci. 2003, 72:2785-2792.
113. Singh M., Khan A.J., Shah P.P., Shukla R., Khanna V.K., Parmar D. Polymorphism in environment responsive genes and association with Parkinson disease. Mol. Cell. Biochem. 2008, 312:131-138.
114. Speiser Z., Katzir O., Rehavi M., Zabarski T., Cohen S. Sparing by rasagiline (TVP-1012) of cholinergic functions and behavior in the postnatal anoxia rat. Pharmacol. Biochem. Behav. 1998, 60:378-393.
115. Stefanova N., Poewe W., Wenning G.K. Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Exp. Neurol. 2008, 210:421-427.
116. Tang Y.P., Ma Y.L., Chao C.C., Chen K.Y., Lee E.H.Y. Enhanced glial cell line-derived neurotrophic factor mRNA expression upon (-)-deprenyl and melatonin treatment. J. Neurosci. Res. 1998, 53:593-604.
117. Tatton W., Chalmers-Redman R., Tatton N. Neuroprotection by deprenyl and other propargylamines: glyceraldehydes-3-phosphate dehydrogenase rather than monoamine oxidase B. J. Neural Transm. 2003, 110:509-515.
118. Thomas C.E., Huber E.W., Ohlweiler D.F. Hydroxyl and peroxyl radical trapping by the monoamine oxidase-B inhibitors deprenyl and MDL 72, 974A: implications for protection of biological substrates. Free Radic. Biol. Med. 1997, 22:733-737.
119. Tsujimoto Y., Shimizu S. VDAC regulation by the Bcl-2 family proteins. Cell Death Differ. 2000, 7:1174-1181.
120. Weinreb O., Bar-Am O., Amit T., Chillag-Talmor O., Youdim M.B.H. Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J. 2004, 18:1471-1473.
121. Weinreb O., Amit T., Sagi Y., Drigues N., Youdim M.B.H. Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson's disease drug, rasagiline compared with selegiline, in the rat brain. J. Neural Transm. 2009, 116:1456-1472.
122. Wu Y.H., Fisher D.F., Swaab D.F. A promotor polymorphism in the monoamine oxidase A gene is associated with the pineal MAOA activity in Alzheimer's disease patients. Brain Res. 2007, 116:13-19.
123. Yi H., Akao Y., Maruyama W., Chen K., Shih J.C., Naoi M. Type A monoamine oxidase is the target of an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, leading to apoptosis in SH-SY5Y cells. J. Neurochem. 2006, 96:541-549.
124. Yi H., Maruyama W., Akao Y., Takahashi T., Iwasa K., Youdim M.B., Naoi M. N-Propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2. J. Neural Transm. 2006, 113:21-32.
125. Yogev-Falach M., Amit T., Bar-Am O., Weinstock M., Youdim M.B.H. The involvement of mitogen-activated protein (MAP) kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline. FASEB J. 2002, 16:1674-1676.
126. Yogev-Falach M., Amit T., Bar-Am O., Youdim M.B.H. The importance of propargyl moiety in the anti-Parkinson drug rasagiline and its derivatives for MAP-dependent amyloid precursor protein processing. FASEB J. 2003, 16:2325-2327.
127. Youdim M.B.H., Bakhle Y.S. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br. J. Pharmacol. 2006, 147:S287-S296.
128. Yu P.H., Davis B.A., Fang J., Boulton A.A. Neuroprotective effects of some monoamine oxidase-B inhibitors against DSP-4-induced noradrenaline depletion in the mouse hippocampus. J. Neurochem. 1994, 63:1820-1828.
129. Yu Y., W Y., Tsai S.J., Hong C.J., Chen T.J., Chen M.C., Yang C.W. Association study of a monoamine oxidase A gene promoter polymorphism with major depressive disorder and antidepressant response. Neuropharmacology 2005, 30:1719-1723.
130. Zhu Q., Chen K., Shih J.C. Bidirectional promotor of human monoamine oxidase A (MAO A) controlled by transcription factor Sp1. J. Neurosci. 1994, 14:7393-7403.